Ofer Rotem

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

Elizabeth Dudnik, Nir Peled, Hovav Nechushtan et al. · Journal of Thoracic Oncology · 2018 · 220 citations · Full text

Medicine, Molecular Genetics, Oncology +14

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee et al. · Journal of Clinical Oncology · 2024 · 142 citations · Full text

Medicine, Oncology, Pharmacology +14

UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)

Jair Bar, Nir Peled, Shiruyeh Schokrpur et al. · Journal of Thoracic Oncology · 2022 · 97 citations · Full text

Medicine, Oncology, Pharmacology +14

Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)

Elizabeth Dudnik, Elias Bshara, Ahuva Grubstein et al. · Lung Cancer · 2018 · 75 citations

Medicine, Immunology, Oncology +14

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data

Elizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg et al. · OncoImmunology · 2021 · 70 citations · Full text

Medicine, Oncology, Pharmacology +15